Cancer Survival Outcomes in Autoimmune Skin Disease Patients Save
Patients with autoimmune skin diseases (ASDs) with cancer had significantly better cancer survival outcomes than those without ASD, suggesting coexistant autoimmune or inflammatory disease does not adversely affect a cancer prognosis.
Using data from Taiwan’s Nationwide Cancer Registry and National Health Insurance Database researchers assessed ASDs affect on cancer prognosis and survival outcomes. They included patients with cancer who received antineoplastic treatment (ie, chemotherapy, targeted therapy, or immunotherapy) and patients with ASDs (alopecia areata, Sjögren syndrome, vitiligo, cutaneous lupus erythematosus, psoriasis, lichen planus, autoimmune bullous diseases, systemic sclerosis, morphea, hidradenitis, and dermatomyositis) to assess all-cause mortality and cancer-specific mortality.
Among 197 895 treated cancer patients, 26 008 had ASD (mean age, 64 years, 58% female). ASD patients had significantly better survival outcomes than those without ASDs (HR 0.94; 95% CI, 0.92-0.96) for all-cause mortality and an SHR of 0.94 (95% CI, 0.92-0.96) for cancer-specific mortality.
This survival advantage was particularly evident in patients with alopecia areata and Sjögren syndrome.
Thisi analysis did not examine the effects of cancer on ASD outcomes.
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.